Interleukin 1 beta recombinant vaccine for treating pulmonary fibrosis and application thereof

Abstract

The invention discloses an IL-1 beta vaccine for treating pulmonary fibrosis. A recombinant PfTrx-IL-1 beta vaccine established by inserting epitope of IL-1 beta into a PfTrx carrier sequence can successfully stimulate an organism to generate high-potency IL-1 beta resistant neutralizing antibody and can obviously relieve pulmonary fibrosis induced by bleomycin. Immunity of the IL-1 beta vaccine can obviously inhibit mouse pulmonary tissue collagen deposition, the vaccine can lower expression level of TGF-beta 1, CTGF and PDGFB in mouse, and these characteristics are highly conducive to slowing down the process of pulmonary fibrosis. Therefore, the IL-1 beta vaccine is expected to be developed into an effective means for treating pulmonary fibrosis.

Description

technical field [0001] The invention belongs to the field of drugs for treating pulmonary fibrosis, and in particular relates to an interleukin 1β recombinant vaccine for treating pulmonary fibrosis and its application. Background technique [0002] Pulmonary fibrosis (or called pulmonary fibrosis, pulmonary fibrosis, PF) is a large group of diseases with chronic inflammation of diffuse alveolar units, proliferation of interstitial fibrous tissue, and deposition of extracellular matrix as the main pathological changes. PF is usually caused by diffuse interstitial lung disease, including dust inhalation, autoimmunity, drugs, radiation or infection, and a considerable number of patients have no clear cause (idiopathic pulmonary fibrosis, IPF). Progressive progression of the disease can eventually lead to irreversible damage to the lung tissue, seriously affecting the patient's respiratory function. In recent years, the incidence of PF has shown an obvious upward trend. There...

AI Technical Summary

Problems solved by technology

[0006] All of the above drugs can specifically antagonize IL-1β, but they have the following disadvantages: ① high price and heavy economic burden for patients; ② anakinra has a short half-life and requires daily injections, which is inconvenient to use and poor in patient dependence, while the clinical efficacy is moderate ; ③It is easy to cause allergies, and the use of drugs can interfere with the patient's normal immune response to new antigens such as vaccines

At the same time, the above-mentioned drugs have not been applied to the treatment of pulmonary fibrosis so far.

Images